Skip to content

Clinical study of pseudomembrane dissection under nasopharyngoscope in preventing nasopharyngeal necrosis after radiotherapy for newly treated M0 nasopharyngeal carcinoma

Clinical study of pseudomembrane dissection under nasopharyngoscope in preventing nasopharyngeal necrosis after radiotherapy for newly treated M0 nasopharyngeal carcinoma

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200064237
Enrollment
Unknown
Registered
2022-10-01
Start date
2022-10-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nasopharyngeal Carcinoma

Interventions

single arm:Pseudomembranous Dissection

Sponsors

Jiangxi Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Nasopharyngeal non-keratinizing carcinoma without distant metastases was initially treated. 2. Suitable for radical radiotherapy, and complete radical radiotherapy. 3. Pseudomembrane reaction occurred in the nasopharyngeal mucosa during and after radiotherapy. 4. Karnofsky score >= 70 points. 5. Expected survival more than 1 year. 6. Induction chemotherapy + concurrent chemotherapy + adjuvant chemotherapy or concurrent chemoradiotherapy + adjuvant chemotherapy or radiotherapy alone are allowed. 7. The patients were able to comply with the study and follow-up procedures, and the patients signed a formal informed consent to demonstrate that they understood that the study was in compliance with the hospital's policy and ethical requirements.

Exclusion criteria

Exclusion criteria: 1. Recurrent radiotherapy for recurrent nasopharyngeal carcinoma; 2. Uncompleted radical radiotherapy; 3. Nasal endoscopic intolerance; 4. Nasal atresia, endoscopic failure; 5. Coagulation dysfunction; 6. Hereditary bleeding constitution; 7. Patients undergoing anticoagulation therapy; 8. Platelets<= 50×10^9/L.

Design outcomes

Primary

MeasureTime frame
1-year nasopharyngeal necrosis rate;

Secondary

MeasureTime frame
Necrosis-Free Survival;Overall Survival;Progression-Free Survival;Time of Pseudomembrane Duration;

Countries

China

Contacts

Public ContactPeng Shiyi

Jiangxi Cancer Hospital

pshiyi6002@aliyun.com+86 13507913152

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026